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Title: Outcomes in Patients With and Without ICD-9 Diagnosed Severe Sepsis and Septic Shock 
Purpose: To evaluate the hypothesis that patients who present to the emergency department with 
objective findings of severe sepsis or septic shock, but who are not specifically diagnosed, 
denoted by absence of 995.92 or 785.52, are treated less aggressively and have worse outcomes 
than similar patients who are specifically diagnosed with severe sepsis or septic shock.  
Design: Retrospective cohort study 
Setting: University of Kansas Hospital, academic medical center, emergency department 
Patients: 6885 patients with severe sepsis or septic shock 
Methods: Data were extracted from the electronic health record using the query tool HERON, to 
identify patients with severe sepsis or septic shock admitted through the emergency department, 
between 11/01/07–09/31/15. Patients aged ≥ 18 years, who had an infection, received an 
antibiotic ≤ 8 hours after triage, and meet criteria for severe sepsis and/or septic shock were 
eligible for inclusion. Severe sepsis was defined either by explicit diagnosis, ICD-9 995.92, or 
clinical criteria, infection + ≥2 sites of organ dysfunction. Septic shock was identified by one of 
the following: 1) an explicit diagnosis of septic shock, ICD-9 785.52, 2) criteria for severe sepsis 
and an ICD-9 code of other shock or shock unspecified (785.50 or 785.59), or 3) criteria for 
severe sepsis and received a vasopressor. We compared treatment rates, based on the Surviving 
Sepsis Campaign three-hour recommendations, and outcome differences between severe sepsis 
and septic shock patients who had a diagnosis code of 995.92 or 785.52 to patients who met 
criteria, but were never diagnosed as denoted by no ICD-9 diagnosis code.  
Main Results: A total of 6885 eligible patients were identified, with a mean age of 60.4 years ± 
16.9 (mean ± standard deviation). Half of patients were male, (51.3%) and 42.5% received an 
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ICD-9 diagnosis code of 995.92 or 785.52. Septic shock was coded more frequently than severe 
sepsis (74.1% vs 32.8%). Three-hour bundle protocol completion rates were low for all patients 
(8.6%), but higher for those with an ICD-9 code than patients without (9.6% vs 7.9%, p=0.02). 
Average time to first antibiotic administration was also earlier for those with a diagnosis code 
(3.2 ± 3.1 hours vs 3.93 ± 3.9 hours, p <0.001). Therapeutic components of the 3-hour protocol, 
administration of an antibiotic and IV fluids if needed, were also found to be administered more 
often in patients with a diagnosis code (34.8% vs 28.6%, p<0.001).  
Within the cohort, 5631 (81.7%) patients had severe sepsis and no shock. Those with an ICD-9 
code of 995.92 had higher mortality (6.3% vs 2.3%), higher ICU admission rates (44.7% vs 
22.5%), and hospital lengths of stay (9.2 ± 6.9 days vs 6.9 ± 6.7 days), (all p<0.001). Discharge 
locations were also different. Severe sepsis patients with an ICD-9 diagnosis code were 
discharged home less (43.6% vs 52.0%, p<0.001), were discharged to hospice more (6.1% vs 
4.4%, p<0.001), and were given home health services more often (22.4% vs 19.5%, p=0.01). 
Readmission rates (30-day) were highest for patients without an ICD-9 code of 995.92 (20.9% vs 
25.5%, p<0.001). Among patients with shock (n=1254, 20.5%), there was no significant 
difference in mortality or post-hospital discharge locations between those with an ICD-9 
diagnosis code of 785.52 and those without. Of interest, patients without an ICD-9 code of 
785.52 had higher ICU admission rates (90.2% vs 83.8%), longer hospital stays (16.7 ± 14.8 
days vs 13.4 ± 12.3 days), and longer ICU stays (7.7 ± 8.2 days vs 5.5 ± 6.2 days), (all p <.001).  
Conclusions: Patients with severe sepsis and septic shock continue to be underdiagnosed as 
evidence by ICD-9 codes and undertreated according to international surviving sepsis guidelines. 
Patients meeting shock criteria are more often diagnosed than those with severe sepsis. Overall, 
treatment rates were sub-optimal, but patients with an ICD-9 diagnosis had higher total and 
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therapeutic component rates. Among septic shock patients without a code, secondary outcomes 
including ICU admission and hospital and ICU length of stays were worse compared to patients 
with an ICD-9 diagnosis code of 785.52. Patients with severe sepsis and without a diagnosis 
code had higher 30-day readmission rates. Further investigation is needed to identify factors 
contributing to ICD-9 code assignments, as well as financial implications of under-coding. 
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Chapter I: Literature Review 
Significance of Severe Sepsis 
Severe sepsis is a life-threatening syndrome caused by a systemic immune response to an 
underlying infection. It is an underestimated principal cause of mortality, and the leading cause 
of death in non-coronary ICUs [3]. The Centers for Disease Control and Prevention reported 
severe sepsis as the 11th leading cause of death in 2009; mortality estimates range from 28.6% to 
51.0% [4]. Those patients who survive hospitalization, as compared to matched controls without 
severe sepsis, experience cognitive decline, have decreased quality of life scores, and have 
higher long term mortality and morbidity [5, 6]. Additionally, the Agency for Healthcare 
Research and Quality listed sepsis as the most expensive condition treated in U.S. hospitals, 
costing more than $16 billion annually [7].  
Underlying medical conditions and increased age can increase the risk of developing 
severe sepsis, as well as influence poor outcomes [8]. The highest incidence of severe sepsis 
occurs among people over 65 years of age. As America’s baby boom generation continues to age 
and the number of patients living with comorbidities such as cancer and HIV continues to 
increase, the incidence, mortality, and costs associated with severe sepsis will continue rising [9]. 
The relationship between severe sepsis and underlying co-morbidities is bi-directional. Not only 
does underlying illness increase the risk for infection and severe sepsis, but survivors are then 
more likely to suffer a higher burden from their existing comorbid medical conditions [8]. This 
series of events could be the initial spiral of major morbidity in our country. Epidemiological 
studies report that the incidence of severe sepsis continues to increase, along with total mortality, 




Definitions of Sepsis, Severe Sepsis, and Septic Shock 
Severe sepsis is a condition caused by an underlying infection triggering an 
inappropriate, systemic immune response and resulting in end organ dysfunction. Normally, in 
response to cellular injury or infection leukocytes and pro-inflammatory mediators such as TNF-
α, IFNγ, IL-1, and IL-6, work to kill invading pathogens and repair damaged cells. These pro-
inflammatory mediators also play a central role in amplification of the immune response by 
activating cellular cascades that recruit more immune cells to the site of infection, increase the 
permeability of the vasculature to allow cell migration to the site of injury, and raise the body’s 
temperature [13]. These basic immune processes are manifested clinically as the systemic 
immune response syndrome, SIRS. SIRS is a sign of an active immune response and consists of 
four markers, listed in Figure 1. The combination of two or more SIRS criteria, coupled with a 
suspected infection, describes a patient with sepsis. A study published in 2015 found that nearly 
87.9% of septic patients have two or more criteria [14]. Even though a small proportion of 
patients, 12%, do not elicit a response to meet the SIRS criteria, SIRS criteria are important early 
signs of sepsis and have a large role in screening patients for the condition. While mortality rates 
at this stage are lower than for 
severe sepsis, at 7-16%, the key to 
positive outcomes is prevention of 
progression to the next stage [4].  
The next stage after sepsis, 
severe sepsis, is defined as acute organ dysfunction in the presence of an underlying infection. 
(Specific acute organ dysfunction sites and descriptions can be found in the appendix.) The 
immune process described above is highly regulated, ensuring it stays localized and controlled. 
Heart Rate >90 bpm 
Respiratory Rate >20 breaths/min 
Temperature ≥ 38⁰C or ≤ 36⁰C 
White Blood Cell Count ≥ 12,000 or ≤ 4,000 
cells/mm3 or > 10% 
bands 




For reasons not precisely known, in some situations this response becomes more robust and 
systemic, involving secondary sites away from the primary site of infection [8]. Pinsky described 
this robust immune response as a form of malignant intravascular inflammation due to its auto-
amplifying nature, spreading uncontrolled within the vascular space and a result of a normal 
immune response gone awry [15]. It is believed that this systemic vascular inflammation is 
caused by an excessive amount of inflammatory mediators. These mediators activate the 
fibrinolytic and coagulation systems causing endothelial damage, increased vascular 
permeability, decreased perfusion of organs, and at the cellular level causing mitochondrial 
dysfunction [13]. Regardless of the exact mechanisms, this profound and systemic immune 
response results in acute organ dysfunction and potentially failure. Mortality estimates for severe 
sepsis range from 21% to 58% [4]. Eventually, without aggressive treatment, the vascular 
compromise becomes so significant that the potentially deadly syndrome of septic shock ensues. 
Septic shock is defined as severe hypotension, refractory to fluid management. This progression 
and classification of sepsis, severe sepsis, and septic shock was proposed in 1991 by the Society 
of Critical Care Medicine (SCCM) and the American College of Chest Physicians (ACCP) to 
help unify the description and diagnosis of these patients and can be visualized in Figure 2 [2].  
 





















Treatment of Severe Sepsis 
Decreased mortality and morbidity in severe sepsis revolves around early recognition and 
aggressive treatment. A consensus committee of international experts and organizations, the 
Surviving Sepsis Campaign (SCC), created international guidelines and recommendations for the 
treatment of severe sepsis and septic shock patients, the Surviving Sepsis Campaign Guidelines 
for Management of Severe Sepsis and Septic shock Patients. Treatment is focused on 
administration of timely antibiotics, controlling the source of infection, and volume resuscitation 
with intravenous fluids (IV fluids) [1]. Based on a large retrospective study involving 32,000 
patient charts across 17 countries, the SCC committee decided to simplify treatment in 2012 by 
creating the SCC sepsis 3 and 6 hour treatment bundles. The components of the sepsis bundles 
can be found in Figure 3. The use of SSC three- and six-hour bundles showed increases in the 
quality improvement of sepsis care and decreases in mortality.  
SSC provides well defined rationale for each bundle component based on the best 
evidence available. A serum lactate measurement provides information about the level of 
hypoperfusion in patients who are not yet hypotensive based on mean arterial pressure, but who 
are at risk. As hyperlactatemia is typically found in septic patients, the lactate level can provide 
Surviving Sepsis Campaign Bundles 
To be completed in three hours: 
1) Obtain blood cultures prior to antibiotic administration 
2) Administer broad spectrum antibiotics 
3) Measure serum lactate levels 
4) Provide 30 mL/kg crystalloid for hypotension or lactate ≥4 mmol/L 
To be Completed within six hours: 
1) For hypotension, non-responsive to initial fluid resuscitation, apply vasopressors to 
maintain a MAP ≥65 mmHg 
2) If hypotension is persistent after fluid resuscitation, or initial lactate ≥4 mmol/L, reassess 
volume and tissue perfusion.  
3) Re-measure lactate if initial lab value was elevated  
 





prognostic information, as those patients with a serum lactate level of ≥4 mmol/L have a 46.1% 
mortality rate [16]. High lactate levels can also alert a provider to initiate treatment with the 
recommended six-hour shock bundle despite not having blood pressures ≤70 mmHg. 
Requirements of a blood culture before antibiotic administration increases the opportunity to 
identify the causative organism and to use the confirmation to de-escalate antimicrobial therapy 
to a more selective agent [1]. Additionally, if a blood culture is drawn after antibiotic 
administration, the likelihood of growing a culture becomes rare, as sterilization of the blood 
occurs quickly, potentially within an hour of administration of an antibiotic [17].  
The two most important components of the bundle, antibiotic administration and IV fluid 
resuscitation are aimed at therapeutic benefit, rather than for diagnostic purposes as are obtaining 
a serum lactate and a blood culture. As the most common source of infection in severe sepsis and 
shock is pneumonia, followed by abdominal infections with Gram-positive and Gram-negative 
organisms, administration of early antibiotics is appropriate in the majority of patients. Evidence 
overwhelmingly supports that administration of early antibiotics reduces mortality in severe 
sepsis patients with a bacterial infection [18]. Kumar showed that patients with septic shock 
havve a linear relationship between time of antibiotic administration and risk of death among 
patients with septic shock. Each hour of delay was associated with a 7.6% decrease in survival 
[19]. Ibrahim found that patients in the intensive care unit (ICU) who received inadequate 
antibiotic treatment experienced higher hospital mortality [20]. The recommendation that a broad 
spectrum antibiotic be given first is based on the reduced margin of error when treating critically 
ill patients. Antibiotic therapy should always be targeted at the suspected pathogen and its 
sensitivity to coverage, but broad coverage is essential when the pathogen is unknown. SCCM 
guidelines even recommend storing pre-mixed quantities of broad spectrum antibiotics in the 
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emergency department to speed in delivery and avoid delays. Lastly, administration of IV fluids 
is necessary to help restore ineffective arterial blood pressure and perfusion of end organs that 
contributes to global tissue hypoxia. As the systemic immune response increases in severe sepsis 
and septic shock, vasodilation, capillary leak, and vascular injury can contribute to significant 
intravascular volume deficits. Patients with a fluid requirement should receive at least 30mL/kg 
of a crystalloid fluids to restore perfusion [17].  
Another key in fighting this rising epidemic is education. Physician education promoting 
the recognition of patients meeting criteria, as well as adherence to standardized treatment 
protocols is essential to prevent unnecessary loss of life. The guidelines recommend screening of 
all infected patients for severe sepsis to increase early identification of patients with sepsis and 
begin early interventions to prevent progression [1]. In 2008, results from a nationwide 
prospective educational intervention in Spain showed that the intervention, aimed at improving 
screening of patients and completion of the SSC sepsis bundles, was capable of decreasing 
nationwide severe sepsis mortality rates [21].  An estimated 490 lives were saved by this one 
year education effort. In the United States, Levy et al. measured treatment compliance rates and 
mortality over a seven year period after the initiation of the Surviving Sepsis Campaign initiative 
in 2004. Their analysis involved 218 medical sites from three continents. At sites with high 
treatment compliance, mortality rates were lower, dropping 0.7% for every quarter of 
participation.  This resulted in a 25% relative risk reduction in mortality, helping prove that 
standardization and performance markers can help change clinical behaviors that improve care 
and ultimately decrease mortality [22]. Despite the positive outcomes associated with protocol 
compliance and early recognition, all epidemiological severe sepsis studies show that the 
condition remains underdiagnosed and undertreated.  
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History of Finding Severe Sepsis Patients Retrospectively in Research 
The majority of published literature relies on retrospective patient cohorts created using 
data extracted from the electronic medical record (EMR) or administrative billing data. The very 
first epidemiological study was conducted by the CDC in 1990, using the National Hospital 
Discharge Survey, estimating 450,000 cases a year, attributing to greater than 100,000 deaths. 
Since then, a variety of epidemiological methods have been used to produce estimates of severe 
sepsis burdens; each has its own limitations.   
In 2001, Angus became one of the first researchers to describe the epidemiology of 
severe sepsis, in the United States. He used a more inclusive method that did not require a 
positive blood culture diagnosis, as only 30-50% of patients have one [1, 23]. Using 
administrative discharge data from hospitals in seven states, the case definition required that 
patients have ICD-9 codes for both an infection and acute organ dysfunction within the same 
encounter. Angus’s final cohort was validated against previous prospective clinical trial data and 
resulted in a relatively simple algorithm that can be used to find an inclusive group of severe 
sepsis patients [3]. Despite the success of this methodology, as noted by the paper’s > 3900 
citations (Web-of-Science), Angus’s method relies solely on ICD-9 codes, not taking into 
consideration the clinical components that measure organ dysfunction such as lab values. 
Without these clinical elements of severe sepsis, elements that may not be reflected within the 
lists of acute organ dysfunctions, severe sepsis is generally underestimated, only capturing those 
patients with severe sepsis who were actually treated [8]. Additionally, Angus’ method does not 
require that the organ dysfunction be separate from the site of infection. As the definition of 
severe sepsis is a systemic immune response, Angus captured a population that consists of 
patients with mostly single site organ dysfunctions, 73% of his cohort [3].  
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Following Angus’ work, the second most cited methodology for finding severe sepsis 
patients was created by Martin, who reviewed data from severe sepsis patients from 1979-2000. 
The Martin method searched the EMR for patients with ICD-9 diagnosis codes for a blood borne 
infection (septicemia, bacteremia, or fungemia) and ICD-9 diagnosis codes for acute organ 
dysfunctions. His searches produced a more specific cohort, with mortalities 10% higher than the 
Angus method and a lower incidence, 140/100,000 cases. As mentioned previously, about 50% 
of severe sepsis patients do not have laboratory positive blood cultures; among those who do, 
there is a higher associated mortality rate [23, 24].  
Since the publication of these two methods, numerous others have replicated their 
algorithms to find severe sepsis patients, all resulting in different numbers. The most recent 
epidemiological studies show annual incidence rates vary 3.5 fold from 300/100,000 to 
1,031/100,000 creating a call for a closer look at the methodology and validity of using 
administrative billing data [25]. Overall, all studies report a rise in incidence and total mortality 
making this an important area of study. Case fatality rates have been declining around 3% a year 
since 1991 [26]. Clinicians postulate that these observations arise from improved treatment and 
identification, as well as an increasing high-risk population [10, 24]. Others believe the rise in 
incidence is attributable to ICD-9 coding changes, such as increased use of organ dysfunction 
coding [27]. Stevenson, et al. compared mortality rates from 36 multicenter clinical trials with 
administrative data to answer the billing changes versus clinical practice improvement debate. 
They hypothesized that the increase in incidence and decline in case fatality was due to increased 
organ dysfunction coding, and that capturing a larger, less acutely ill cohort, led to a fall in 
mortality rates. After standardizing for case-mix differences, they found that from 1991-2009, 
from all forms of identification (Martin, Angus, and prospectively using clinical trial data), case 
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fatality rates dropped and incidence rates increased [26]. Additionally, regardless of the method, 
Angus or Martin, mortality estimates derived from administrative data ICD-9 algorithms are 
comparable to prospective trial cohorts, and thereby likely are accurate.  





Chapter II: Thesis Introduction 
Severe sepsis is a major public health problem in the United States. It is the leading cause 
of mortality in non-coronary ICUs, as well as the most expensive condition treated in U.S. 
hospitals [3, 7]. As the population continues to age and the number of people living with 
comorbid medical conditions continues to increase, the incidence and overall mortality from 
severe sepsis will likely continue to rise. Although the condition is highly lethal, early 
recognition and aggressive treatment decrease mortality and morbidity [22, 28]. Despite this fact, 
studies continue to show that patients meeting severe sepsis criteria are underdiagnosed [3, 25]. 
In 2004, sepsis-specific ICD-9 codes 995.92 and 785.52 were created to administratively 
capture patients meeting the international consensus definitions of severe sepsis and septic 
shock. Multiple studies, as well as local chart review adjudications, continue to show that these 
explicit sepsis related ICD-9 diagnosis codes are underused by physicians and coders [10, 24, 25, 
29, 30]. In Gaieski’s study of epidemiological methods to identify severe sepsis patients, he 
found that patients who met Martin’s criteria, requiring presence of a blood borne infection, were 
more likely to have received a sepsis-related ICD-9 code [25]. In 2013, Whittaker evaluated the 
sensitivity and specificity for detecting severe sepsis patients by using sepsis related ICD-9 
diagnosis codes for cohort extraction. She found that explicit diagnosis codes had a sensitivity of 
21% when compared with the Angus method. Both methods showed that patients with a sepsis 
related diagnosis code represented a more severely ill population, based on higher Acute 
Physiology and Chronic Health Evaluation (APACHE) II scores, higher serum lactate levels, and 
higher ICU admission rates [25, 30]. To date, this is the only study that investigated the 
differences between patients who did or did not receive a sepsis related ICD-9 diagnosis code. 
We previously showed that of patients meeting clinical criteria for severe sepsis, 48.4% were 
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never assigned an explicit ICD-9 diagnosis code of 995.92 and/or 785.52 [29]. This led us to 
question whether these un-coded severe sepsis patients represent an unrecognized, and 
potentially undertreated group of patients with severe sepsis.  
After a physician recognizes that a patient meets criteria for severe sepsis, within three 
hours the provider should initiate and complete components of the international evidence-based 
guidelines for treatment of severe sepsis [1]. The combination of drawing a blood culture and a 
serum lactate, administration of a broad spectrum antibiotic, and administration of fluids if the 
patient is hypotensive is known as the Surviving Sepsis Three Hour Bundle. Performance of 
these actions is specifically indicated for patients recognized as having severe sepsis and septic 
shock.  
We hypothesized that a smaller proportion of patients who met clinical criteria for severe 
sepsis, but who were not specifically given a sepsis-related ICD-9 diagnosis code, would receive 
care according to these guidelines for treatment in comparison with patients who were 
specifically diagnosed as having severe sepsis or septic shock using an ICD-9 code. We also 
hypothesized that the mortality and morbidity would be higher in this un-coded group as 
measured by hospital and ICU length of stays, 30-day readmission rates, and discharge to 
locations beyond home. Our primary objective was to compare treatment, mortality, and other 
patient-centered outcomes among severe sepsis patients with a sepsis related ICD-9 diagnosis 
code, 995.92 or 785.52, with the same outcomes among patients who met clinical criteria for 




Chapter III: Methods 
 
Study Approval 
Our study was approved by the University of Kansas Institutional Review Board with a waiver 
of informed consent, IRB STUDY00001753. 
Data Source 
Data were collected from the electronic medical record, (EMR), at the University of Kansas 
Medical Center using an i2b2 based interface, the Healthcare Enterprise Repository for 
Ontological Narration (HERON) [31]. Using HERON, a query tool that extracts information 
from the EMR based on researcher selection of discrete data fields, we created a Boolean search 
method to find a cohort of severe sepsis patients who entered through the emergency department 
and were treated between 11/01/2007, the initiation date for the institution’s EMR, and 
09/30/2015, the last date before conversion to ICD-10 diagnosis codes. Flowsheet data not 
captured by the HERON interface were electronically obtained after the final cohort of severe 
sepsis and/or septic shock patients were identified by the Office of Organizational Improvement 
matching MRN and triage dates.  
Case Selection 
All patients were required to meet the following inclusion criteria: ≥ 18 years of age, admission 
through the emergency department, received an ICD-9 diagnosis code for acute infection, given 
an antibiotic within 24 hours of triage, and had recorded clinical outcomes, such as hospital 
length of stay and discharge disposition codes. ICD-9 diagnosis codes for infection can be found 






After meeting the above inclusion criteria, patients were retained if they the met case definition 
of severe sepsis or septic shock. Using a modified Angus method, based on the clinical criteria 
proposed by the American College of Chest Physicians/Society of Critical Care Medicine 
Consensus definitions, we defined patients as having severe sepsis if either a diagnosis code of 
995.52 was given or there was documented presence of an infection plus ≥2 different sites of 
organ dysfunction [2]. Acute organ dysfunction was defined by presence of either an acute organ 
dysfunction code or on the basis of whether the first laboratory or physiologic value recorded in 
the patient record met the threshold of organ dysfunction [32]. Laboratory threshold values and 
lists of codes for infections and acute organ dysfunctions can be found in the appendix. Patients 
with septic shock were similarly defined by having a septic shock specific ICD-9 diagnosis code 
of 785.52, or if they met severe sepsis criteria and were administered a vasopressor 
(norepinephrine, epinephrine, vasopressin, or phenylephrine), or met severe sepsis criteria and 
received a diagnosis of shock unspecified or other shock. Patients were excluded from the final 
cohort if they were under the age of 18 years, had cardiogenic shock (ICD-9 code of 785.51), did 
not meet criteria for severe sepsis, or were not given an antibiotic within 8 hours of triage. 
Outcome Measures and Statistical Analysis  
Data cleaning and analysis were performed using SAS software, Version 9.4, using two-sided 
hypothesis testing (alpha 0.05) (Copyright 2012-2013 SAS Institute Inc., Cary, NC). All binary 
outcomes were analyzed using chi-square test statistics, and data consisting of numerical 
continuous data were evaluated using a Student’s t-test. Our primary outcomes were treatment 
completion rates and mortality compared between the groups of patients diagnosed with an ICD-
9 code specific to severe sepsis or septic shock (995.92 or 785.52) and the group with no such 
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ICD-9 code. Outcome measures including information about death, hospital and ICU length of 
stays, final discharge location, and 30-day readmission rates were calculated using information 
from the University Health Consortium (UHC) data embedded within the electronic medical 
record. Treatment completion rates were calculated and analyzed in accordance with the 
Surviving Sepsis Campaign Three Hour Bundle Guidelines [1]. Each component of the protocol 
(blood culture ordered, serum lactate ordered, antibiotics administered, IV fluids given) was first 
analyzed independently and, if completed, the patient received a score of 1 (yes) on that 
component. All four components were summed for a total treatment score out of 4. If the patient 
scored a 4, they were considered to have the bundle protocol successfully completed within three 
hours of triage. If less than four, the patient did not meet bundle completion. The proportion of 
patients who received the complete bundle was calculated. Additionally, therapeutic components 
of the bundle, use of broad spectrum antimicrobials within three hours and intravenous fluids if 
hypotensive, were analyzed together and reported as a frequency.  
Patients with the first recorded MAP < 70mmHg or the first serum lactate ≥ 4 mmol/L 
were classified as having a need for fluids. All patients who had a need and received 30mL/kg 
within the first 2.5 hours of triage received a fluid completion score of 1, as did patients without 
a need. We chose to limit fluid times to 2.5 hours within triage time to prevent overestimate of 
the actual fluid received by a patient. Other outcomes including mortality, 30-day readmission, 
and discharge location are expressed as a frequencies, while average lengths of stay were 
reported as an average number of days.  
To evaluate potential reasons for coding and treatment differences, we measured 
presentation illness status by calculating a sequential organ failure assessment (SOFA) score, 
using the first laboratory and physiological values recorded. Additionally, we calculated the 
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number of infection sites, number of significant co-morbidities using a Charleson co-morbidity 
score, and a total number of acute organ dysfunctions.  
We conducted multivariate logistic regression analysis to find the most accurate 
predictors of receiving an ICD-9 diagnosis code of 995.92 or 785.52, as well as independent 
predictors of receiving complete treatment within the first three hours of admission while 
controlling for potential confounding. The results are presented as odds ratios and 95% 
confidence intervals.  
Lastly, as outcome differences between severe sepsis and septic shock patients are 
already known to be significantly different, we analyzed severe sepsis and septic shock patient 
outcomes separately to prevent confounding by the presence of septic shock. 
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Chapter IV: Results 
Cohort Characteristics  
A total of 6,885 patients were identified with severe sepsis or septic shock (Figure 4). 
The mean age was 60.4 ± 16.9 years (mean ± SD), and 51.6% (n=3534) were male. About one-
fifth of the total cohort met criteria met criteria for septic shock (n=1254, 18.2%) (Table 1). 
Overall, 42.5% of patients (n=2927) had a sepsis related ICD-9 diagnosis code. Those 
with a diagnosis code had more documented infections (2.4 vs 1.8), were more likely to have a 
diagnosis of bacteremia or septicemia (93.7% vs 22.2%), and had more organ dysfunction sites 
(3.2 vs 2.6), (all p< 0.001) (Table 2). When further separated based on presence or absence of 
shock, the significant difference in the number of organ dysfunction sites between ICD-9 
positive and negative groups disappeared among patients with severe sepsis, but not patients with 
septic shock patients (Table 3). Other baseline acute organ dysfunction, as measured by initial 
lactate levels (2.6 vs 2.2 mmol/L) and SOFA scores (3.9 and 3.1), were higher in the ICD-9 
diagnosed group (p<0.001) even when separated based on presence of shock (Table 4).  
Using multivariate logistic regression (odds ratio: 95% confidence interval), we found 
that having a diagnosis of bacteremia/septicemia, (OR: 25.1, 17.2-36.7), being admitted to the 
ICU (OR: 3.3, 2.8-3.8), and having a diagnosis of a respiratory tract infection or respiratory 
dysfunction, (OR 1.40, 1.2-1.6) were all independently associated with receiving a sepsis-
specific ICD-9 diagnosis code. Age, gender, number of comorbidities, and number of organ 
dysfunction sites were not found to be predictive. Overall model fit was assessed using the 
Hosmer and Lemeshow Goodness-of-Fit Test, (p=0.5). Components of the final model can be 





Figure 4. Cohort Organization  
*68 patients assigned 785.52 never received 995.92 and 861 received both. **151 patients meeting 
criteria for septic shock received an ICD-9 diagnosis code of 995.92, but not 785.52. 104 of these patients 
were identified by administration of a vasopressor and had no other diagnosis code of shock. 37 received 
a diagnosis of shock unspecified, 785.50 and 16 a diagnosis code of other shock, 795.59.  
 














     
Age, (mean ± SD) 60.4 ± 16.9 59.5 ± 17.3 61.1 ± 16.7 p=0.03 
Gender,    male n (%) 3534 (51.3%) 1510 (51.6%) 2024 (51.1%) p=0.72 
Race      White, n (%) 4536 (65.9%) 1920 (65.6%) 2616 (66.1%) p=0.056 
Black, n (%) 1614 (23.4%) 667 (22.8%) 947 (23.9%)  
Other, n (%) 725 (10.5%) 333 (11.4%) 392 (9.90%)  
Charleston 
Comorbidity Score 
(out of 21 ± SD) 
6.1 ± 3.6 6.2 ± 3.5 5.9 ± 3.6 p<0.001 
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Measures of Infection     
Sites of Infection  
(mean ± SD) 
2.0 ± 0.9 2.4 ± 0.9 1.8 ± 0.8 p<0.001 
Infectious Codes (001-
0139.99) 
5399 (78.4%) 2861 (97.8%) 2538 (64.1%) p<0.001 
Bacteremia/Septicemia  3624 (52.6%) 2744 (93.7%) 879 (22.2%) p<0.001 
Respiratory 3130 (45.5%) 1499 (51.2%) 1631 (41.2%) p<0.001 
Urinary 2703 (39.3%) 1199 (41.0%) 1504 (38.0%) p=0.01 
Soft Tissue Site 1236 (17.9%) 561 (19.2%) 675 (17.1%) p=0.02 
Abdomen 731 (10.6%) 385 (13.2%) 346 (8.74%) p<0.001 
 
Table 3. Presentation Acute Organ Dysfunctions for Severe Sepsis Patients 










First Serum Lactate  
(mean ± SD) 
2.2 ± 1.6 2.3 ± 1.7 2.1 ± 1.5 p<0.001 
Average SOFA score 3.0 ± 2.1 2.9 ± 2.2 3.1 ± 2.0 p<0.001 
First MAP (mean ± 
SD) 
92.3 ± 20.3 91.8 ± 20.6 92.5 ± 20.2 p=0.23 
Organ Dysfunction 
Sites (mean out of 7 ± 
SD)  
2.6 ± 1.0 2.6 ± 1.3 2.6 ± 0.8 p=0.06 
Renal 3145 (56.8%) 1024 (58.3%) 2121 (56.1%) p=0.12 
Hematological 2922 (52.7%) 821 (46.7%) 2101 (55.5%) p<0.001 
Respiratory 2170 (39.2%) 849 (48.3%) 1321 (34.9%) p<0.001 
Cardiovascular 1444 (26.1%) 437 (24.9%) 1007 (26.6%) p=0.17 
CNS 1665 (30.0%) 529 (30.0%) 1136 (30.0%) p=0.97 
*105 (1.8%) patients had one or more components necessary to calculate a complete SOFA score 
missing, 2236, (39.7%) never had a serum lactate taken, and 73 (1.3%) had an unattainable 





Table 4. Baseline Acute Organ Dysfunctions of Septic Shock Patients 
 All Septic 
Shock Patients 
N=1254 







First Serum Lactate 
(mean ± SD) 
2.97 ± 2.79 3.04 ± 2.86 2.75  ± 2.55 p=0.04 
SOFA score  
(mean out of 21 ± SD) 
5.4 ± 3.32 5.65 ± 3.39 4.68 ± 3.01 p=0.01 
First MAP  
(mean ± SD) 
81.4 ± 22.1 79.7 ± 21.3 86.4 ± 23.5 p=0.03 
Organ Dysfunction Sites 
(mean out of 7 ± SD)  
4.13 ± 1.38 4.20 ± 1.43 3.95 ± 1.20 p<0.001 
Respiratory 867 (69.1%) 628 (67.6%) 239 (73.5%) p=0.05 
Hematological 832 (66.3%) 626 (67.4%) 206 (63.3%) p=0.20 
Cardiovascular 1254 (100%) 929 (100%) 325 (100%) p=1.00 
CNS 511 (40.8%) 385 (41.4%) 126 (38.7%) p=0.43 
Renal 882 (70.3%) 680 (73.1%) 202 (62.1%) p<0.001 
*22 (1.7%) patients had one or more components necessary to calculate a complete SOFA score 
missing, 326, (26.0%) never had a serum lactate taken, and 22 (1.7%) had an unattainable first 
MAP. They were excluded from the respective calculation. 
 
Treatment Differences  
A total of 6885 patients were included in the bundle completion calculation. Those 
patients with a sepsis related ICD-9 diagnosis code (995.92 and/or 785.52) had higher total 
bundle protocol completion, all four components met under three hours, than those without a 
code (9.6% vs 7.9%, p <0.001). Therapeutic component completion rates (a broad spectrum 
antibiotic and appropriate fluids) were higher than total bundle protocol completion rates for the 
whole cohort (31.2% vs 8.6%) and also higher for those with an ICD-9 diagnosis code (34.8% vs 
28.6%, p<0.001). All individual protocol component completion rates were higher in those with 
a diagnosis code than those without. The largest percentage of the 1458 (21.2%) patients who 
required fluid resuscitation were those with a diagnosis code, (58.0%, n=845). A majority of 
patients without a need for IV fluids (n=5427) did not have a diagnosis code (61.6%). Among 
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these patients with a fluid need, those with a diagnosis code were more likely to receive 
appropriate fluids than patients without a code (25.6% vs 11.4%, p<0.001).  
Blood culture completion was the most common of all four components completed in 
both patients with a code and without (76.5% vs 54.4%) and obtaining a serum lactate was the 
least completed (29.7% vs 27.4%). The average time to first antibiotic administration was 3.6 +/- 
1.9 hours for the whole cohort. The group of patients with a diagnosis code were given 
antibiotics about 45 minutes sooner than patients without a diagnosis code, (3.2 +/- 3.1 hours vs 
3.9 +/- 3.9 hours, p <0.002). Only 48.0% of patients received an antibiotic within three hours of 
triage as recommended, but 75.7% appropriately received a broad spectrum antibiotic as their 
first dose (Figure 5). When the cohort was divided based on presence or absence of septic shock, 
similar trends were seen.  
 
Figure 5. Three Hour Bundle Completion Rates by Presence or Absence of ICD-9 Diagnosis 




































Patients with a diagnosis code Patients without a diagnosis code
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Using multivariate logistic regression (odds ratio: 95% confidence interval), we found no 
good model to predict receiving all four components of treatment within three hours. Receiving 
therapeutic components, a broad spectrum antibiotic and IV fluids, the most significant 
independent predictors of receiving treatment, completed bundle protocol or therapeutic 
components alone to be: having a respiratory infection (OR: 1.56, 1.43-1.78), receiving a sepsis 
specific ICD-9 diagnosis code (OR: 1.24, 1.10-1.36), presence of respiratory dysfunction (OR: 
1.25, 1.12-1.40), and age (OR: 1.006, 1.00-1.01). Gender, race, number of comorbidities, and 
markers of acute organ dysfunction including SOFA scores, first lactates, and total number of 
organ sites involved were not found to be predictive. Overall model fit was assessed using the 
Hosmer and Lemeshow Goodness-of-Fit Test, (p=0.41). Components of the final model can be 
found in the appendix. 
Due to a higher presence of respiratory infections in patients with a diagnosis code (51% 
vs 41%, Table 1), and because respiratory infection was independently predictive of receiving 
treatment, we performed a sub-analysis of treatment rates for patients with and without diagnosis 
codes while controlling for respiratory infections (Figure 6). 3130 severe sepsis or septic shock 
patients had a respiratory infection, 52% received a diagnosis code and 48% did not (p=0.02). 
While controlling for the presence of a respiratory infection, differences in overall bundle 
treatment and therapeutic component treatment rates between patients with and without a 
diagnosis code no longer differed. Yet, patients with a diagnosis code continued to have higher 
rates of individual components completed. Time to first antibiotic remained similar, being 
administered almost 45 minutes earlier in patients with a diagnosis code than those without (3.2 




Figure 6. Three Hour Bundle Completion Rates While Controlling for Presence of Pneumonia by 
Presence or Absence of ICD-9 Diagnosis Code Specific to Severe Sepsis or Septic Shock 
 
Outcomes for Patients with Severe Sepsis and No Shock 
A total of 5631 (81.7%) patients had severe sepsis without shock criteria. Overall severe 
sepsis mortality was 3.6%. Mortality was significantly higher among those patients with a sepsis-
specific ICD-9 diagnosis code (6.3% vs 2.3%, p<0.001). Patients with a diagnosis code also had 
higher rates of ICU admission (44.7% vs 22.5%), longer hospital length of stays (9.2 ± 9.4 vs 6.9 
± 6.7 days), and higher rates of discharge with home healthcare services (22.4% vs 19.5%), (all 
p<0.01). Readmission rates (30-day) were highest among those patients without a diagnosis 






































Patients with a diagnosis code
Patients without a diagnosis code
23 
 
Table 5. Outcomes of Patients with Severe Sepsis and No Shock 
 
Outcome Measures 




995.92 (+) Cases 
 
995.92 (-)  Cases 
 
P values 
 5631 (81.7%) 1847 (32.8%) 3784 (67.2%)  
Mortality, % 204 (3.6%) 117 (6.3%) 87 (2.3%) p<0.001 
Hospital Length of 
Stay (mean days ± SD)  
7.6 ± 7.7** 9.2 ± 9.4 6.9 ± 6.7 p<0.001 
ICU Length of Stay 
(mean days ± SD) 
3.7 ± 4.2** 4.0 ± 4.5 3.5 ± 3.9 p=0.02 
ICU Admission Rate 1679 (29.8%) 826 (44.7%) 853 (22.5%) p<0.001 
30-Day Readmission 
Rate 
1352 (24.0%) 397 (21.5%) 955 (25.2%) p=0.02 
Discharge Location     
Home 2771 (49.2%) 805 (43.6%) 1966 (52.0%) p<0.001 
Home, with Home 
Health Services 
1151 (20.4%) 414 (22.4%) 737 (19.5%) p=0.01 
Rehab 129 (2.3%) 42 (2.3%) 87 (2.30%) p=1.0  
Acute Nursing Care 855 (15.2%) 269 (14.6%) 586 (15.5%) p=0.38  
Long Term Care 109 (1.9%) 46 (2.5%) 63 (1.7%) p=0.04 
Hospice 281 (5.0%) 113 (6.1%) 168 (4.4%) p<0.001 
**Length of stays were calculated excluding patients who died during the encounter. Results 
were similar when these patients remained included.  
 
Outcomes for Patients with Septic Shock 
A total of 1254 (18.2%) patients met septic shock criteria. Most (69.7%, n=1147) had an 
ICD-9 code of 785.52 of which 75% (n=861) also were assigned a diagnosis code of 995.92. 
Overall septic shock mortality was 20.5%. No significant difference in mortality was seen 
between patients with and without a sepsis-specific ICD-9 diagnosis code (21.7% vs 16.9%, 
p=0.07). Additionally, no statistically significant differences were seen in 30-day readmission 
rates (20.9% vs 25.5%, p=0.10) or specific locations of discharge including home, home with 
home health services, or long term care facilities. Measures of resource utilization were higher in 
patients who did not receive a diagnosis code including ICU admission rates, (83.8 % vs 90.2%, 
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p<0.001), ICU length of stay (5.50 ± 6.16 vs 7.73 ± 8.18 days, p<0.001), and hospital length of 
stay (13.4 ± 12.3 vs 16.7 ± 14.8 days, p<0.001).    
Table 6. Outcomes of Patients with Septic Shock 
Outcome Measures All patients with 
shock criteria 
785.52 (+) Cases 785.52 (-)  Cases P values 
 N=1254 (18.2%) N=929 (74.1%) N=325 (25.9%)  
Mortality, % 257 (20.5%) 202 (21.7%) 55 (16.9%) p=0.07 
Hospital Length of 
Stay (mean days ± SD)  
14.3 ± 13.1** 13.4 ± 12.3** 16.7 ± 14.8** p<0.001 
ICU Length of Stay 
(mean days ± SD) 
6.14 ± 6.87** 5.50 ± 6.16** 7.73 ± 8.18 ** p<0.001 
ICU Admission Rate 1071 (85.4%) 778 (83.8%) 293 (90.2%) p=0.005 
30-Day Readmission 
Rates 
278 (22.2%) 195 (20.9%) 83 (25.5%) p=0.10 
Discharge Location     
Home 312 (24.9%) 230 (24.8%) 82 (25.2%) p=0.88 
Home, with Home 
Health Services 
242 (19.3%) 180 (19.4%) 62 (19.1%) p=0.94 
Rehab 50 (3.99%) 31 (3.34%) 19 (5.85%) p=0.07 
Acute Nursing Care 211 (16.8%) 155 (16.7%) 56 (17.2%) p=0.86 
Long Term Care 74 (5.90%) 50 (5.38%) 24 (7.40%) p=0.22 
Hospice 84 (6.70%) 62 (6.67%) 22 (6.77%) p=1.0 
**Length of stays were calculated excluding patients who died during the encounter. Results 





 Chapter V: Discussion  
We present a retrospective study of 6885 patients with severe sepsis or septic shock 
admitted through the emergency department at a single academic medical center in Kansas City, 
KS. It is the largest study to-date investigating treatment and outcome differences between 
patients with and without sepsis-specific ICD-9 diagnosis codes. We hypothesized that patients 
with sepsis-specific ICD-9 diagnosis codes, 995.92 or 785.52 represented a formally diagnosed 
group of severe sepsis patients, and that those severe sepsis and septic shock patients without 
these codes would be an under recognized and undertreated group of patients. Consistent with 
previous studies, we found that patients meeting clinical criteria for severe sepsis and septic 
shock continue to be underdiagnosed as evidenced by over half of the cohort lacking sepsis-
specific ICD-9 diagnosis codes (57.5%) [3, 10, 25]. Overall, the highest rate of code assignment 
was seen among patients with septic shock (74%), but unlike Gaieski’s 2013 study, we found 
high rates of patients who received an ICD-9 for both septic shock and severe sepsis (68.7%) 
[25]. We believe this reflects increased familiarity with 995.92 and 785.52 by physicians and 
coders over the last decade.  
This is the first study to find that patients without sepsis specific ICD-9 diagnosis codes 
are undertreated based on the Surviving Sepsis three hour bundle guidelines. We found that 
patients with a sepsis-specific ICD-9 diagnosis code received individual bundle components and 
the complete 3-hour bundle protocol more often than those without an ICD-9 diagnosis code, 
though these are still not optimal among even the patients with a diagnosis code. Having a 
diagnosis code was also independently associated with receiving treatment after adjusting for 
other possible factors in multivariate analysis. We believe this signifies that patients without a 
diagnosis code are not simply un-coded patients, but a group of patients that go under recognized 
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and undertreated. A potential limitation of our modeling analysis was that overall low treatment 
rates might have prevented us from capturing the best predictors. We found only one marker of 
acute organ dysfunction that significantly predicted who received treatment. It’s possible that 
physicians associate severe sepsis with markers of acute inflammation and infection, such as the 
SIRS criteria, that were not captured in this study and that their presence would have better 
predicted administration of the bundle treatment protocol. Of interest, the most significant 
predictor of receiving the three hour bundle was having a respiratory infection. It is well known 
that the respiratory tract is the most common site of infection in patients with severe sepsis [3]. It 
is possible that pay for performance initiatives such as PN-5b, requiring early antibiotic 
administration in patients with pneumonia confound our findings [33]. When controlling for 
pneumonia, individual treatment rates still remained higher in patients who received a diagnosis 
code while the complete 3-hour bundle protocol and therapeutic components were no longer 
significantly different. It’s also possible that physicians associate severe sepsis with specific 
characteristics, such as respiratory infections or advanced age and potentially miss less apparent, 
but equally important sites of infection such as the urinary tract or soft tissues. However, age was 
not associated with receiving a diagnosis code in our study. 
We additionally focused on the therapeutic components of the three hour bundle protocol. 
Again, those without an ICD-9 diagnosis code were undertreated when compared to patients with 
an ICD-9 diagnosis code. Nationwide surveys of emergency department physicians and nurses 
have identified several barriers to early administration of the three hour bundle protocol. The 
third most common listed by physicians and the number one described by nurses was lack of 
identification of patients who meet severe sepsis criteria [34, 35] . This is also the first study to 
report similar baseline measures of acute organ dysfunction when comparing patients with and 
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without ICD-9 diagnosis codes. It is possible, as described by these surveys, that severe sepsis 
patients are a challenging and heterogeneous population to identify in the emergency department.  
We also hypothesized that patients without an ICD-9 diagnosis would experience worse 
outcomes. We found this to be only partially true and specific to patients meeting septic shock 
criteria. Patients without an ICD-9 diagnosis code of 785.52 had worse outcomes as measured by 
higher ICU admission rates and hospital and ICU length of stays. Patients without a diagnosis 
code had statistically equivalent mortality rates compared to those with an ICD-9 diagnosis code. 
We believe this is a reflection of inadequate treatment rates within the critical hours of 
presentation. As described by Kumar, the strongest predictor of mortality in patients with septic 
shock was time to antibiotic [19]. In our cohort, those without an ICD-9 diagnosis code, time to 
first antibiotic was 1.35 hours later than those with a diagnosis code (Appendix Table 6).  
Unlike shock patients, patients with a severe sepsis diagnosis code of 995.92 had worse 
clinical outcomes compared to patients without a code. We found that all ICD-9 coded patients 
had a higher number of infections, were more frequently diagnosed with septicemia, and had a 
higher number of total organ dysfunction sites [25, 36]. It is possible that severe sepsis patients 
who are not formally diagnosed are a less acutely ill population and, despite being less 
aggressively treated, experienced better outcomes [36]. Unlike previous studies, beyond baseline 
differences just described, we demonstrated patients with and without ICD-9 diagnosis codes had 
similar illness presentations in the emergency room based on first mean arterial pressure and 
lactate values, as well as SOFA scores using the first recorded laboratory and physiologic 
measurements. Again, it is possible that better markers of acuity that would prompt treatment or 
describe predictors of poor outcomes were not included in this study. Despite lower mortality, 
patients without an ICD-9 code of 995.92 had higher 30-day readmission rates. A known risk 
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factor for 30-day readmission rates in severe sepsis patients is inadequate treatment during the 
primary hospitalization [37].  
Our study raises more questions than it answers, but the findings from this study provide 
direction for moving forward. Acknowledging low treatment rates, based on three hour bundle 
protocol completion, and low identification of severe sepsis patients, the next step is identifying 
factors that prevent early treatment initiation and recognition of these patients in the emergency 
department. Educational interventions have been shown to increase recognition, physician 
adherence to treatment protocols, and ultimately patient outcomes [21].  
Finally, financial implications of under coding and long term outcomes beyond 30 days 
are of interest. The average cost of a sepsis hospitalization is double the cost of a stay for another 
diagnosis and when not coded correctly, and reimbursement can be significantly lower [38]. 
Resource utilization by patients, specifically of those with septic shock and without an ICD-9 
diagnosis code, was significantly higher based on higher ICU admission rates and longer lengths 
of ICU and hospital stays and severe sepsis patients without an ICD-9 code had higher 30-day 
readmission rates. It is possible that our hospital is being under reimbursed due to inadequate 
physician coding practices. Prior, during a hospital specific chart review, only 2 out of 100 charts 
had a diagnosis of severe sepsis or septic shock defined by the presence of a written diagnosis of 
severe sepsis or septic shock, but never received a formal ICD-9 diagnosis code [29]. This, in 
addition to evidence of under treatment found in this study, supports a hypothesis that physicians 
are underdiagnosing and undertreating severe sepsis and septic shock cases and it results in 




Our study has several limitations. Generalizability to other institutions and hospital 
settings may be restricted as our study was confined to patients admitted through a single center 
emergency department. As data were extracted from the EMR, quality is limited to the quality of 
data entry during the initial hospitalization. Our retrospective design also limits our ability to 
determine a true directional relationship between physician recognition, sepsis specific bundle 
treatment completion, and ICD-9 diagnosis code assignment. It is also possible that not all 
patients presented to the ED with criteria for severe sepsis and/or septic shock at the initial triage 
time, and only developed the condition later during the hospitalization; affecting the accuracy of 
subsequent analysis. We do believe that requiring patients to have had an antibiotic within 8 
hours and ≥ 2 sites of organ dysfunction, using both ICD-9 diagnosis codes and laboratory 
values, helps increase the likelihood of acute infection and organ dysfunction on presentation. 
Lastly, due to the large size of our cohort, interpretations of statistically significant findings 
require clinical judgment when making interpretations about the differences between groups.  
Considerations for Future Research 
This study highlights a concerning finding that severe sepsis and septic shock patients are 
being underdiagnosed and undertreated within our own facility. It is of interest to measure ICD-9 
diagnosis code rates, as well as bundle completion rates after a planned educational intervention 
to boost provider recognition and treatment based on international guidelines. It would be of use 
to survey physicians about the assignment of sepsis-related ICD-9 diagnosis codes to further 
understand why patients are being assigned a code (or not being assigned) and barriers to code 
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Appendix B: ICD-9 Infection List 
 
ICD9 Codes ICD-9 Code Description 
001.0 – 139.99 Infectious & Parasitic Infections  
320.0 – 326.99 Meningitis, encephalitis, abscess, phlebitis and thrombophlebitis 
420.0 - 421.9 Acute pericarditis and endocarditis 
451.0 - 451.9 Phlebitis and thrombophlebitis 
461.0 - 465.9 Sinusitis, pharyngitis, tonsillitis, URI’s, laryngitis, bronchitis, and 
bronchiolitis 
481 - 482.9  485 - 486 Pneumonia and bronchopneumonia 
491.21 Obstructive chronic bronchitis with (acute) exacerbation 
494.0 - 494.1 Bronchiectasis 
510 - 510.9 Empyema 
513 - 513.1 Abscess of lung or mediastinum 
540.0, 540.1, 540.9 - 542, 
566 
Appendicitis 
562.01-562.11 Diverticulitis of small intestine (without hemorrhage) 
562.13 Changes in vascular appearance of retina 
567.0 - 567.9 Peritonitis 
569.5 - 569.83 Abscess or perforation of intestine 
572.0 - 572.1 Abscess of liver 
575 Cholecystitis 
590.0 - 590.9 Chronic pyelonephritis 
599 UTI/Urethral infection 
601 - 601.9 Prostatitis 
614 Acute salpingitis and oophoritis 
616.9 Unspecified inflammatory disease of cervix vagina and vulva 
670.00- 670.04 Major puerperal infection 
681 - 681.9 Cellulitis, abscess, onychia, and paronychia of digits 
686 - 686.1 Pyoderma 
686.8 - 686.9 Other local infections, skin & subcutaneous 
711.00- 711.99 Arthritis 
730.00 -730.99 Osteomyelitis 
790.7 Bacteremia 
996.6 - 996.69 Infection and inflammatory reaction due to device implant and 
graft 
998.51 Infected post operative seroma 
998.59 Acute reaction to foreign substance accidentally left during a 
procedure 














ICD-9 Description & Code 
Neurological Glasgow Coma Scale < 15 Encephalopathy Unspecified 384.30 
Metabolic Encephalopathy, 348.31 
Other Encephalopathy 348.30  
Transient Mental Disorder 293.9 
Anoxic Brain Damage, 348.1 
Hematological Partial Thromboplastin 
Time 
Platelet Count  
INR  
D-dimer  
> 60 sec 
 
< 100,000 /μL 
> 1.5 
> 230  
Defibrination Syndrome, 286.6 
Thrombocytopenia, 287.5 
Secondary Thrombocytopenia, 287.4 
Other and unspecified coagulation 
defects, 286.9  
Respiratory  Arterial 02 saturation 
PaO2  
< 90%  
< 70% 
Acute respiratory failure 518.81 
Cardiovascular Systolic Blood pressure 
MAP  
Received a vasopressor** 
< 90 mmHg 
< 65 mmHg 
 
Hypotension 458.0 
Shock w/o trauma 785.5 
Septic Shock 785.52 
Other shock, no trauma 785.59 
Hepatic Bilirubin, total  
ALT  
AST 
> 2 mg/dL 
> 90 U/L 
> 90 U/L 
Acute and subacute necrosis of the 
liver, 570 
Hepatic infarction 573.4 
Renal  Creatinine  >2 mg/dL Oliguria and anuria, 788.5 
Acute Kidney Failure, 584 
Lactic acidosis Lactate >2mmol/L  
 
*Required 2 or more different organ systems be compromised, from any combination of the 7 
systems listed, plus one ICD-9 infection code to meet criteria for severe sepsis. All lab values 
were sorted by first measurement date and only included as an acute organ dysfunction if it met 
threshold. **Vasopressor types for cardiovascular dysfunction included dobutamine, dopamine, 













Appendix D: Cohort Characteristics for Patients with Severe Sepsis and No Septic Shock 
 







 N=5631 N=1847 (32.8%) 3784 (67.2%)  
Age, (mean ± SD) 60.6 ± 17.2 61.2 ± 16.7 59.5 ± 18.0 P<0.001 
Gender, male n (%) 2872 (51.0%) 933 (50.5%) 1939 (51.2%) P=0.61 
Race        White, n (%) 3710 (65.9%) 1198 (64.9%) 2512 (66.4%)  
Black, n (%) 1339 (23.8%) 436 (23.6%) 903 (23.9%)  
Other n, (%) 576 (10.2%) 210 (11.4%) 366 (9.67%)  
Sites of Infection  
(mean ± SD) 
1.95 ± 0.88 2.31 ± 0.82 1.78 ± 0.84 P<0.001 
Bacteremia/Septicemia 4229 (75.1%) 1806 (97.8%) 2423 (64.0%) P=0.001 
Respiratory 2516 (44.7%) 957 (51.8%) 1559 (41.2%) P=0.001 
Urinary 2176 (38.6%) 741 (40.1%) 1435 (37.9%) P=0.11 
Soft Tissue Site 986 (17.5%) 336 (18.2%) 650 (17.2%) P=0.35 
Abdomen 523 (9.29%) 194 (10.5%) 329 (8.69%) P=0.03 
First Serum Lactate 
(missing=2562, 37%) 
(mean ± SD) 
2.21 ± 1.61 2.33 ± 1.73 2.13 ± 1.53 P<0.001 
Average SOFA score 
(missing=105, 1.8%) 
3.02 ± 2.08 2.89 ± 2.17 3.07 ± 2.03 P<0.001 
First MAP (mean ± 
SD) 
(missing=73, 1.0%) 
92.3 ± 20.3 91.8 ± 20.6 92.5 ± 20.2 P=0.23 
Organ Dysfunction 
Sites (mean out of 7 ± 
SD) (missing=89, 
1.3%) 
2.58 ± 0.99 2.62 ± 1.29 2.56 ± 0.82 P=0.06 
Renal 3145 (56.8%) 1024 (58.3%) 2121 (56.1%) P=0.12 
Hematological 2922 (52.7%) 821 (46.7%) 2101 (55.5%) P<0.001 
Respiratory 2170 (39.2%) 849 (48.3%) 1321 (34.9%) P<0.001 
Cardiovascular 1444 (26.1%) 437 (24.9%) 1007 (26.6%) P=0.17 
CNS 1665 (30.0%) 529 (30.0%) 1136 (30.0%) P=0.97 
Charleston 
Comorbidity Score 
(out of 21 ± SD) 







Appendix E: Cohort Characteristics for Patients Septic Shock 
 
 All Septic 
Shock Patients 





 N=1254 929 (74.0%) 325 (26.0%)  
Age, (mean ± SD) 59.6 ± 15.9 59.6 ± 16.1 59.7 ± 15.2 P=0.20 
Gender, male n (%) 662 (52.8%) 497 (53.5%) 165 (50.8%) P=0.42 
Race        White, n (%) 826 (65.9%) 625 (67.3%) 201 (61.8%)  
Black, n (%) 275 (21.9%) 194 (20.9%) 81 (24.9%)  
Other n, (%) 149 (11.9%) 107 (11.5%) 42 (12.9%)  
Sites of Infection  
(mean ± SD) 
2.37 ± 0.95 2.45 ± 0.92 2.14 ± 0.99 P=0.10 
Bacteremia/Septicemia 1170 (93.3%) 908 (97.7%) 262 (22.4%) P<0.001 
Respiratory 614 (49%) 466(50.2%) 148 (45.5%) P=0.16 
Urinary 527 (42.0%) 392 (42.2%) 135 (41.5%) P=0.85 
Soft Tissue Site 250 (20.0%) 194 (20.9%) 56 (17.2%) P=0.17 
Abdomen 208 (16.6%) 161 (17.3%) 47 (14.5%) P=0.26 
First Serum Lactate 
(missing=2562, 37%) 
(mean ± SD) 
2.97 ± 2.79 3.04 ± 2.86 2.75  ± 2.55 P=0.035 
Average SOFA score 
(missing=105, 1.8%) 
5.4 ± 3.32 5.65 ± 3.39 4.68 ± 3.01 P=0.01 
First MAP (mean ± 
SD) 
(missing=73, 1.0%) 
81.4 ± 22.1 79.7 ± 21.3 86.4 ± 23.5 P=0.03 
Presence of Shock 1254 (100%) 1254 (100%) 1254 (100%)  
Organ Dysfunction 
Sites (mean out of 7 ± 
SD) (missing=89, 
1.3%) 
4.13 ± 1.38 4.20 ± 1.43 3.95 ± 1.20 P<0.001 
Respiratory 867 (69.1%) 628 (67.6%) 239 (73.5%) P=0.05 
Hematological 832 (66.3%) 626 (67.4%) 206 (63.3%) P=0.20 
Cardiovascular 1254 (100%) 929 (100%) 325 (100%) P=1.00 
CNS 511 (40.8%) 385 (41.4%) 126 (38.7%) P=0.43 
Renal 882 (70.3%) 680 (73.1%) 202 (62.1%)  
Charleston 
Comorbidity Score 
(out of 21 ± SD) 










Appendix F: Multivariate logistic regression model of adjusted odds ratios for being 
assigned as sepsis specific ICD-9 diagnosis code of 995.52 or 785.52.  
Overall model choice was based on using Hosmer and Lemeshow Goodness-of-Fit Test, Chi-
squared value, 2.7, p=0.53.  
Predictors of a sepsis 
specific ICD-9 diagnosis 








ICD-9 diagnosis code 
25.1 17.2 – 36.7 
ICU Admission 3.3 2.8 – 3.9 
Hypotension 1.4 1.2 – 1.7 
Respiratory Infection 1.4 1.2 – 1.6 
Respiratory Organ System 
Dysfunction 
1.4 1.2 – 1.7 
Total Infection Sum 1.3 1.2 – 1.5 
First Lactate Values 1.1 1.1 – 1.2 
 
Appendix G: Multivariate logistic regression model of adjusted odds ratios for receiving 
therapeutic components of the bundle protocol.  
Overall model choice was based on using Hosmer and Lemeshow Goodness-of-Fit Test, Chi-
squared value, 8.24, p=0.410.  
Predictors of receiving 
therapeutic components 
of treatment in final 
model 
Adjusted 




Age  1.01 1.00-1.01 
Sepsis specific ICD-9 
diagnosis code (995.52 or 
785.52) 
1.22 1.10 – 1.36 
Respiratory Infections 1.60 1.42 – 1.78 
































 5631 1847 (32.8%) 3784 (67.2%)  
All 4 Components  491 (8.7%) 189 (10.2%) 302 (8.0%) p<0.005 
Blood Culture 3483 (61.9%) 1411 (76.3%) 2072 (54.8%) p<0.001 
Lactate measured 
within 3 hours 
1589 (28.2%) 541 (29.3%) 1048 (27.7%) p=0.23 
Broad Spectrum given 
under three hours 
2087 (37.1%) 801 (43.4%) 1286 (34.0%) p<0.001 
Given Under Three  2593 (46.1%) 1010 (54.7%) 1583 (41.8%) p<0.001 
First Dose Broad 
spectrum  
4271 (75.8%) 1402 (75.9%) 2869 (75.8%) p=0.97 
Time to Antibiotic 
(mean hours ± SD) 
3.7 ± 1.9  3.3 ± 1.9  3.9 ± 1.9  p<0.001 
Appropriate Fluids 4825 (85.7%) 1549 (83.9%) 3276 (86.6%) p<0.001 
IV Fluids Needed 
(n=22 missing)  
928 (16.5%) 371 (20.1%) 557 (14.8%) p<0.001 
IV Fluids given at 
30mL/Kg among only 
those with a need 
133(14.3%) 74 (19.6%) 59 (10.6%) p<0.001 
Therapeutic 
Components  
































 1254 1080 (86.1%) 174 (13.9%)  
All 4 Components  103 (8.2%) 92 (8.5%) 11 (6.3%) P=0.37 
Blood Culture 906 (72.3%) 827 (76.6%) 79 (45.4%) P<0.001 
Lactate measured 
within 3 hours 
365 (29.1%) 327 (30.3%) 38 (21.8%) P=0.02 
Broad Spectrum given 
under three hours 
5562 (44.8%) 512 (47.4%) 50 (28.7%) P<0.001 
Given Under Three  713 (56.9%) 650 (60.2%) 63 (36.2%) P<0.001 
First Dose Broad 
spectrum  
938 (74.8%) 817 (75.7%) 121 (69.5%) P=0.09 
Time to First Antibiotic 
(mean hours ± SD) 
3.2 ± 1.9 3.0  ± 1.9 4.4 ± 2.2 P<0.001 
Appropriate Fluids 867 (69.1%) 747 (69.2%) 120 (69.0%) P=1.0 
IV fluids needed 530 (42.6%) 474 (43.9%) 56 (33.9%) P=0.02 
Fluids given at 
30mL/Kg among only 
those with a need 
153 (28.9%) 142 (30.0%) 11 (19.6%) P=0.12 
Therapeutic 
Components  
383 (30.5%) 352 (32.6%) 31 (17.8%) P<0.001 
 
